DSIP (emideltide): what the research says. | Reddit

DSIP is a nonapeptide, nine amino acids long, with a molecular weight of 849. A 1984 review in Neuroscience and Biobehavioral Reviews described it as inducing mainly delta sleep in rabbits, rats, mice and humans, with a more pronounced effect on REM sleep in cats.

The name records an observation rather than a mechanism. A 2006 review in the Journal of Neurochemistry noted that the DSIP gene, the protein and any related receptor had not been isolated.

Yes. Emideltide is the name that appears in US compounding and FDA advisory material; DSIP and delta sleep-inducing peptide are the names the research literature uses. Almost the entire published record is filed under DSIP, which is why a search on emideltide returns very little and a search on DSIP returns four decades of work. A regulatory document naming emideltide and a 1984 paper naming DSIP are describing the same nonapeptide.

The 2006 Journal of Neurochemistry review gives the origin plainly: DSIP was isolated from rabbit cerebral venous blood by the Schoenenberger and Monnier group in Basel in 1977 and was initially regarded as a candidate sleep-promoting factor.

There is no settled mechanism. Without an isolated gene, protein or receptor, the sleep hypothesis has no molecular anchor, and the 2006 review describes it as extremely poorly documented and still weak. What the literature offers instead is a set of proposals built from observed effects.

The human sleep studies are small, old and mixed, and the field’s own reviews are their harshest critics. A 1981 double-blind crossover study in six normal volunteers gave DSIP as a slow intravenous infusion at 25 nmol/kg in the morning. Subjects reported a feeling of sleep pressure, and median total sleep time rose by 59 percent in the 130 minutes after treatment compared with placebo. A second 1981 study, in Experientia, gave the same dose to six middle-aged people with chronic insomnia and reported sleep promotion only in the second hour after injection, with a slight arousing effect indicated in the first.

Nine human entries span twenty years. Several are open reports rather than controlled trials.

The largest human numbers in the DSIP record are not sleep studies. In a 1983 report in Neuropsychobiology, DSIP at 25 nmol/kg was given intravenously as the sole treatment to 67 patients with withdrawal symptoms, 28 from alcohol and 39 from opiates. Twenty-seven percent were lost or unsuitable for evaluation. Of the 49 evaluable patients, a beneficial effect was reported in 48, with an immediate onset of action. A 1984 paper in European Neurology gave DSIP intravenously to 107 inpatients on the same opiate-receptor hypothesis.

The animal record is broader than the human one and less consistent. Two cat studies three years apart disagree on what DSIP does to REM sleep.

There is no approved dose, because there is no approved indication. The doses below are a description of the published record rather than guidance. The figure that recurs in humans is 25 nmol/kg as a slow intravenous infusion.

No human pharmacokinetic profile appears in the record above. The nearest thing the literature offers is a time course of observed effect: the 1981 insomnia study reported a sleep-enhancing effect visible for up to six hours of night sleep. That describes when something was observed, not how fast the peptide cleared.

There is no modern controlled safety dataset for DSIP, which is a statement about the absence of evidence rather than a claim of safety. The record contains one explicit tolerability statement: the 1981 Experientia study reported no daytime sedation and no other side effects in six people at 25 nmol/kg intravenously. Six subjects on a single acute dose is not a safety profile.

The precise answer is more specific than legal or illegal. DSIP is not an FDA-approved drug. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a compounded medication qualifies for its regulatory exemptions only if the bulk substance has a USP monograph, is a component of an approved drug, or appears on the FDA 503A Bulks List. Emideltide is none of those.

The practical effect is that compounding it falls outside those exemptions, which makes the resulting product an unapproved new drug and exposes the pharmacy to FDA enforcement. That is an enforcement posture rather than a prohibition naming the substance, and it is the reason no established pharmacy network supplies it. The position remains under review and can change.

On July 23 and 24, 2026, the FDA Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A Bulks List and recommended six of them: BPC-157, KPV, TB-500, MOTs-C, Semax and Epitalon. Emideltide was the one it did not recommend.

The votes are non-binding. Nothing was added to the 503A Bulks List as a result. An advisory committee recommendation is an input to an FDA decision, not the decision, and the regulatory picture described in the previous section is the picture today.

Six of the seven peptides on the July 2026 agenda drew a recommendation and one did not. The right column reads the same for every row.

It is sold online by research-chemical vendors, typically labelled for research use only and not for human consumption. That label is what allows the sale, and it is also an explicit statement by the seller that they are not offering a medicine.

Anything a licensed US pharmacy dispenses has to clear the regulatory bar first. Every dose PepScribe dispenses is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain.

If the underlying goal is recovery, energy or resilience as you age, there are therapies a licensed physician can prescribe and a licensed US pharmacy can prepare. That is a materially different proposition from a research chemical of unverified contents.